DOCSLIB.ORG

Uses and Administration 55 Micrograms Into Each Nostril Once Daily

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

1649 needed during the course of treatment. A dose of 1 to mg Triamcinolone Hexacetonide 4 may be used for visualisation during vitrectomy. (BAN, USAN, riNN) ® For doses used in children, see below. Other esters of triamcinolone that have occasionally been used include the acetonide dipotassium phosphate, acetonide hemisuccinate, aminobenzal benzamidoisobuty­ rate, and benetonide. Flupamesone (triamcinolone aceto­ nide metembonate) has also been used. Administration in children. Triamcinolone acetonide and hexacetonide have been used for intra-articular injec­ Ph. Eur. 8: tion in children. Although unlicensed in the UK for use (Triamcinolone). A white or almost white, in children under 6 years of age, the BNFC includes doses crystalline powder. It shows polymorphism. Practically for injection into larger joints in those aged from 1 to 18 insoluble in water and in dichloromethane; slightly soluble years. A dose of triamcinolone acetonide 2 mglkg may be in methyl alcohol. Protect from light. used, to a usual maximum of 40 mg, or triamcinolone USP 36: (Triamcinolone). A white or practically white, hexacetonide 1 mglkg to a usual maximum of 20 mg. odourless, crystalline powder. Very slightly soluble in water, However, higher doses have been used. Treatment may be in chloroform, and in ether; slightly soluble in alcohol and repeated for relapse if necessary, although each joint in methyl alcohol. Pharmacopoeias. In Bur. (see p. vii) and US. should usually be treated no more than 3 or 4 times in a year. Ph. Eur. 8: (Triamcinolone Hexacetonide). A white or In the treatment of allergic rhinitis triamcinolone almost white, crystalline powder. Practically insoluble in acetonide may be given by a nasal spray. Children aged 6 Triamcinolone Acetonide (BANM, rJNNMJ ® water; sparingly soluble in dehydrated alcohol and in to 12 years may be given 1 spray (55 micrograms) into each methyl alcohol. Protect from light. Acet (lido cte •'friamdno!Otm:. Trf�n•dnofor{ a�et (lld; nostril once daily. This dose may be increased to 2 sprays £ � USP 36: (Triamcinolone Hexacetonide). A white to cream­ Triarncinoiona, . &<;et(lpido .de; Triarncinolona<;etonld; Tri­ ( 110 micrograms) into each nostril once daily for control of de; coloured powder. Practically insoluble in water; soluble in am<:if1olone, .· t;cetonide. Tria(rldnoloni · �cet�mkl urni severe symptoms. The lowest effective dose should be used Triamdflolor1o <>cetcmi0<J:;; Triamcynolonu acetc>nid; Tri;lm­ chloroform; slightly soluble in methyl alcohol. once symptoms have been controlled. In children aged from sinolon t;setonid:_. T(iamsinoloniasetonidi; rpvtaM!ilH!:!OilOHa 2 to 5 years, the recommended and maximum dose is Uses and Administration 55 micrograms into each nostril once daily. Triamcinolone is a corticosteroid with mainly glucocorticoid Asthma. Corticosteroids and beta2-adrenoceptor agonists activity (p. 1597.1); 4mg of triamcinolone is equivalent in form the cornerstone of the management of asthma (see anti-inflammatory activity to about 5 mg of prednisolone. It p. 1600.3). is used, either in the form of the free alcohol or in one of the Intramuscular triamcinolone acetonide has been esterified forms, in the treatment of conditions for which reported to be more effective than oral low-dose prednisone corticosteroid therapy is indicated (see p. 1597.3 ), except in controlling exacerbations in patients with severe, adrenocortical insufficiency for which hydrocortisone with chronic, life-threatening asthma, 1 although this conclusion supplementary fludrocortisone is preferred. is controversiai.2·7 The dose may be expressed in terms of the base, and the I. Ogirala RG, et a!. High-dose intramuscular triamcinolone in severe, Pharmacopoeias. In Chin., Bur. (see p. vii), Jpn, and US. following are each equivalent to about 10mg of triamcino­ chronic, life-threatening asthma. N Eng! J Med 1991; 324: 589-9. lone: Correction. ibid.; 1380. d 2. Salmeron S, et al. Intramuscular triamcinolone in severe asthma. N Eng! Chin. also inclu es Triamcinolone Acetonide Acetate. triamcinolone acetonide ll mg • J Med 1991; 325: 429-30. triamcinolone acetonide sodium phosphate 14 mg Ph. Eur. 8: (Triamcinolone Acetonide). A white or almost • 3. Nicholas SS. Intramuscular triamcinolone in severe asthma. N Eng! 1 Mfd triamcinolone diacetate 12 mg 1991; 325: 430. white, crystalline powder. It shows polymorphism. • triamcinolone hexacetonide 14 mg 4. Kidney JC, et al. Intramuscular triamcinolone in severe asthma. N Eng! J Practically insoluble in water; sparingly soluble in alcohol. • Med 1991; 325: 430. Protect frmn light. However, esterification generally alters potency and 5. Capewcll S, Mcleod DT. Intramuscular triamcinolone in severe asthma. compounds with equivalent triamdnolone content may N Eng! J Med 1991; 325: 430. USP 36: (Triamcinolone Acetonide). A white to cream­ not have equivalent clinical effect. 6. Ogirala RG, et al. Intramuscular triamcinolone in severe asthma. N Eng! J coloured crystalline powder, having not more than a slight For oral dosage triamcinolone is used in doses ranging Med 1991; 325: 431. odour. Practically insoluble in water; sparingly soluble in 7. Capewell S, McLeod D. Injected corticosteroids in refractory asthma. from 4 to 48 mg daily. Lancet 1991; 338: 1075-6. dehydrated alcohol. in chloroform, and in methyl alcohol. For parenteral use the acetonide ester is given in doses of Store at a temperature of 2 5 degrees, excursions permitted about 40 to 80 mg by intramuscular injection. It is between 15 degrees and 30 degrees. usually given as a suspension to provide a prolonged Chronic obstructive pulmonary disease. Inhaled corticos­ systemic effect. A single dose of 40 to 100 mg of the teroids may be used in chronic obstructive pulmonary dis­ acetonide may provide symptomatic control throughout the ease (see p. 1603.1). Triamcinolone Acetonide Sodium pollen season for hay fever sufferers (but see Rhinitis, Phosphate (BANM. USAN. rJNNMI ® p. 1650.1). The diacetate ester has also been given Eye disorders. Intravitreal injection of triamcinolone intramuscularly. acetonide has been tried in the management of eye disor­ CL-61 965; cL-106359; Fos�ato i.le sodio del ' atetol)ido de For intra-articular injection triamcinolone acetonide, ders characterised by oedema and the abnormal prolifera­ triamcinolona; triamcfnotona. acetonido de.fosfzitode sodio diacetate, and hexacetonide have all been used. Doses for tion of intra-ocular cells. Promising results have been del; Triamcinolone. Acetpnlde, . Phosphate Sodique de; these esters have typically been in the range of 2.5 to 40 mg, reported in diabetic macular oedema, L2 cystoid macular Triamcino!onl Acetonidi Natrici Phosphas; TpMaMu!'fHOnoHa depending upon the size of the joint injected. oedema, and oedema associated with retinal vein occlu­ 1\ceTOH�A& Ha;p11A Qoc<(>ar. For topical application in the treatment of various skin sion.2·5 It has also been used in age-related macular Triamcinokme aq;tooiel\';2hiispdium phosph<Jte: disorders triamcinolone acetonide is used, usually in degeneration (p. 880.2; better results being seen when it is C24H30FNa209P"'55&.40 creams, lotions, or ointments containing 0.1% although combined with photodynamic therapy), in proliferative CA S i 997·1:5·5. concentrations ranging from 0.025 to 0.5% have been diabetic retinopathy, and in the management of some employed. Several topical preparations also contain an forms of cataract and non-infectious uveitis.2•3 Complica­ ATC -- AOlA(Ol,' P.03BA06; SO IBA05. antimicrobial drug. For recommendations concerning the tions of treatment may include raised intra-ocular pressure ATCVer QA (JIACo l; Q[)07t�B09," '(�H612Al�IJ8. correct use of corticosteroids on the skin, and a rough guide (IOP)6 and both infectious and non-infectious endophthal­ 0-" QC05AA I2; mitis 2 Patients with a baseline lOP greater than 16mmHg CJR0 1 AD II; QR03BA06; QSO IMO.'i. to the clinical potencies of topical corticosteroids, see p. 1599.2. or receiving a second injection should be carefully moni­ Triamcinolone esters are also commonly used by tared, as they may be at greater risk of an increase; moni­ intralesional or intradermal injection in the treatment toring should continue beyond 6 months 6 of some inflammatory skin disorders such as keloids. Dissolved drugs are not retained in the eye for prolonged Suggested doses for the various esters have been: periods, and early studies and off-label treatment have used acetonide: to 3 mg per site with no more than 5 mg injectable suspensions to achieve long-lasting concentra­ • I injected into any one site or not more than 30 mg in total tions of triamcinolone in the vitreous bodyJ However, these if several sites of injection are used commercial products were intended for intramuscular and diacetate: a total of 5 to 25 mg, injected as no more than intra-articular use and not licensed for intravitreal injection, • 100 micrograms/cm2 of skin surface area and there has been concern about the potential ocular hexacetonide: up to 500 micrograms per square inch toxicity of their preservative, benzyl alcohoJ.2·7 Various • (about 80 microgramslcm2) of affected skin techniques, such as sedimentation, centrifugation, and In the treatment of allergic rhinitis (p. 1650.1) triamcino­ 1 filtration, have been used extemporaneously to reduce the lone acetonide may be given by a nasal spray in a usual benzyl alcohol content of such products, but the quantity of initial dose of 2 sprays ( 110 micrograms) into each nostril triamcinolone in the final preparation may be altered once daily, reduced to 1 spray (55 micrograms) into each depending on the technique used.8 More recently, nostril once daily when control is achieved. preservative-free products have been licensed in the USA Pharmacopoeias. In US. Preservative-free suspensions of triamcinolone acetonide for intravitreal use ( Triesence; Alcon, USA and Tn·varis; see Uses and Administration, above). USP 36: (Triamcinolone Diacetate). A fine, white to off­ are available for intravitrea1 injection (see Eye Disorders, Allergan, USA - white, crystalline powder, having not more than a slight below). A dose of 4mg is used for the treatment of I.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al

    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Role of Corticosteroids in Treatment of Vitiligo

    Role of Corticosteroids in Treatment of Vitiligo

    Chapter 9 Role of Corticosteroids in Treatment of Vitiligo Nooshin Bagherani Additional information is available at the end of the chapter http://dx.doi.org/10.5772/48384 1. Introduction Vitiligo is the most frequent pigmentary disorder ( Bagherani et al., 2011; Nazer et al., 2011;Yaghoobi et al., 2011a; as cited in Wolff et al., 2007). It is an acquired, idiopathic and progressive skin disease (Bagherani et al., 2011; Shameer et al., 2005; Yaghoobi et al., 2011a), characterized by sharply demarcated depigmented lesions on any part of the body (Van Geel et al., 2004). This disease can also affect hair and mucosal areas such as mouth and genitalia (Gawkrodger et al., 2010). Vitiligo usually begins after birth (Gawkrodger et al., 2010). Regarding the studies retrieved from PubMed since 1995, it has been shown that approximately 50% of the vitiligo cases have its onset before the age of 20 years and 25% before the age of 14 years (Kakourou, 2009). The incidence rate of vitiligo is between 0.1-2% of the world population ( Bagherani et al., 20011; Yaghoobi et al., 2011a,b; as cited in Alkhateeb et al., 2003). Its incidence in those with racially pigmented skin is higher, although reliable figures are not available (Burns et al., 2004; Howitz et al., 1977) . The prevalence has been reported as high as 4% in some South Asian, Mexican and American populations ( Parsad et al., 2003; Sehgal & Srivastava, 2007; Szczurko & Boon, 2008). Both sexes are equally afflicted by vitiligo (Krϋger et al., 2011; Njoo & Westerhof, 2001; Wolf et al.,2007) . In some studies, a female preponderance has been reported ( Burns at al., 2004; Howitz et al.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
  • Pruritus: Scratching the Surface

    Pruritus: Scratching the Surface

    Pruritus: Scratching the surface Iris Ale, MD Director Allergy Unit, University Hospital Professor of Dermatology Republic University, Uruguay Member of the ICDRG ITCH • defined as an “unpleasant sensation of the skin leading to the desire to scratch” -- Samuel Hafenreffer (1660) • The definition offered by the German physician Samuel Hafenreffer in 1660 has yet to be improved upon. • However, it turns out that itch is, indeed, inseparable from the desire to scratch. Savin JA. How should we define itching? J Am Acad Dermatol. 1998;39(2 Pt 1):268-9. Pruritus • “Scratching is one of nature’s sweetest gratifications, and the one nearest to hand….” -- Michel de Montaigne (1553) “…..But repentance follows too annoyingly close at its heels.” The Essays of Montaigne Itch has been ranked, by scientific and artistic observers alike, among the most distressing physical sensations one can experience: In Dante’s Inferno, falsifiers were punished by “the burning rage / of fierce itching that nothing could relieve” Pruritus and body defence • Pruritus fulfils an essential part of the innate defence mechanism of the body. • Next to pain, itch may serve as an alarm system to remove possibly damaging or harming substances from the skin. • Itch, and the accompanying scratch reflex, evolved in order to protect us from such dangers as malaria, yellow fever, and dengue, transmitted by mosquitoes, typhus-bearing lice, plague-bearing fleas • However, chronic itch lost this function. Chronic Pruritus • Chronic pruritus is a common and distressing symptom, that is associated with a variety of skin conditions and systemic diseases • It usually has a dramatic impact on the quality of life of the affected individuals Chronic Pruritus • Despite being the major symptom associated with skin disease, our understanding of the pathogenesis of most types of itch is limited, and current therapies are often inadequate.
  • Treatment Options for Atopic Dermatitis LUCINDA M

    Treatment Options for Atopic Dermatitis LUCINDA M

    Treatment Options for Atopic Dermatitis LUCINDA M. BUYS, PHARM.D., B.C.P.S., Siouxland Medical Education Foundation, Sioux City, Iowa Atopic dermatitis is a common inflammatory skin condition that usually affects children. It is a chronic disease, with periods of remission and flare-ups, that adversely affects the quality of life of patients and their families. Aggressive therapy with emollients is an important intervention for patients with atopic dermatitis. Patients should avoid individual disease triggers and aller- gens. Topical corticosteroids are the mainstay of treatment for flare-ups and are the standard to which other treatments are compared. Topical calcineurin inhibitors should not be used in patients younger than two years or in those who are immunosuppressed, and should be second- line therapies in other patients. Rarely, systemic agents (e.g., cyclosporine, interferon gamma-1b, oral corticosteroids) may be considered in adults. (Am Fam Physician 2007;75:523-8, 530. Copy- right © 2007 American Academy of Family Physicians.) T Patient information: A handout on atopic topic dermatitis is the most com- T-helper type 2 cells, leading to increased dermatitis, written by the mon childhood skin disorder in interleukin-4 production, which promotes author of this article, is developed countries.1 The prev- IgE production. provided on page 530. alence of atopic dermatitis has Atopic dermatitis can have a significant Aincreased two- to threefold in the last three impact on morbidity and quality of life. Chil- decades, affecting 15 to 20 percent of young dren may be affected by itching and associ- children.2 Clinical findings of atopic derma- ated sleep disturbance, the social stigma of titis are variable but can be categorized into a visible skin condition, and the need for three groups of diagnostic features: essential, frequent application of topical medications important, and associated (Table 1).3 Atopic and physician visits.
  • Effect of Intra-Articular Triamcinolone Vs Saline on Knee

    Effect of Intra-Articular Triamcinolone Vs Saline on Knee

    Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021 Downloaded From: https://jamanetwork.com/ on 09/28/2021
  • 2018 Medicines in Development for Skin Diseases

    2018 Medicines in Development for Skin Diseases

    2018 Medicines in Development for Skin Diseases Acne Drug Name Sponsor Indication Development Phase ADPS topical Taro Pharmaceuticals USA acne vulgaris Phase II completed Hawthorne, NY www.taro.com AOB101 AOBiome acne vulgaris Phase II (topical ammonia oxidizing bacteria) Cambridge, MA www.aobiome.com ASC-J9 AndroScience acne vulgaris Phase II (androgen receptor degradation Solana Beach, CA www.androscience.com enhancer) BLI1100 Braintree Laboratories acne vulgaris Phase II completed Braintree, MA www.braintreelabs.com BPX-01 BioPharmX acne vulgaris Phase II (minocycline topical) Menlo Park, CA www.biopharmx.com BTX1503 Botanix Pharmaceuticals moderate to severe acne vulgaris Phase II (cannabidiol) Plymouth Meeting, PA www.botanixpharma.com CJM112 Novartis Pharmaceuticals acne vulgaris Phase II (IL-17A protein inhibitor) East Hanover, NJ www.novartis.com clascoterone Cassiopea acne vulgaris Phase III (androgen receptor antagonist) Lainate, Italy www.cassiopea.com Medicines in Development: Skin Diseases ǀ 2018 Update 1 Acne Drug Name Sponsor Indication Development Phase CLS001 Cutanea acne vulgaris Phase II (omiganan) Wayne, PA www.cutanea.com DFD-03 Promius Pharma acne vulgaris Phase III (tazarotene topical) Princeton, NJ www.promiuspharma.com DMT310 Dermata Therapeutics moderate to severe acne vulgaris Phase II (freshwater sponge-derived) San Diego, CA www.dermatarx.com finasteride Elorac severe nodulocystic acne Phase II (cholestenone 5-alpha Vernon Hills, IL www.eloracpharma.com reductase inhibitor) FMX101 Foamix moderate to severe
  • (Phacs) in the Snow Deposition Near Jiaozhou Bay, North China

    (Phacs) in the Snow Deposition Near Jiaozhou Bay, North China

    applied sciences Article Characterization, Source and Risk of Pharmaceutically Active Compounds (PhACs) in the Snow Deposition Near Jiaozhou Bay, North China Quancai Peng 1,2,3,4, Jinming Song 1,2,3,4,*, Xuegang Li 1,2,3,4, Huamao Yuan 1,2,3,4 and Guang Yang 1,2,3,4 1 CAS Key Laboratory of Marine Ecology and Environmental Sciences, Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, China; [email protected] (Q.P.); [email protected] (X.L.); [email protected] (H.Y.); [email protected] (G.Y.) 2 University of Chinese Academy of Sciences, Beijing 100049, China 3 Laboratory for Marine Ecology and Environmental Science, Pilot National Laboratory for Marine Science and Technology (Qingdao), Qingdao 266237, China 4 Center for Ocean Mega-Science, Chinese Academy of Sciences, Qingdao 266071, China * Correspondence: [email protected]; Tel: +86-0532-8289-8583 Received: 20 February 2019; Accepted: 8 March 2019; Published: 14 March 2019 Abstract: The occurrence and distribution of 110 pharmaceutically active compounds (PhACs) were investigated in snow near Jiaozhou Bay (JZB), North China. All target substances were analyzed using solid phase extraction followed by liquid chromatography coupled to tandem mass spectrometry.A total of 38 compounds were detected for the first time in snow, including 23 antibiotics, eight hormones, three nonsteroidal anti-inflammatory drugs, two antipsychotics, one beta-adrenergic receptor and one hypoglycemic drug. The total concentration of PhACs in snow ranged from 52.80 ng/L to 1616.02 ng/L. The compounds found at the highest mean concentrations included tetracycline (125.81 ng/L), desacetylcefotaxime (17.73 ng/L), ronidazole (8.79 ng/L) and triamcinolone diacetate (2.84 ng/L).
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0099225A1 Freund Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2009/0099225A1 Freund Et Al

    US 20090099225A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0099225A1 Freund et al. (43) Pub. Date: Apr. 16, 2009 (54) METHOD FOR THE PRODUCTION OF Related U.S. Application Data PROPELLANT GAS-FREE AEROSOLS FROM (63) Continuation of application No. 1 1/506,128, filed on AQUEOUSMEDICAMENT PREPARATIONS Aug. 17, 2006, now Pat. No. 7,470,422, which is a continuation of application No. 10/417.766, filed on (75) Inventors: Bernhard Freund, Gau-Algesheim Apr. 17, 2003, now abandoned, which is a continuation (DE); Bernd Zierenberg, Bingen of application No. 09/331,023, filed on Sep. 15, 1999, am Rhein (DE) now abandoned. (30) Foreign Application Priority Data Correspondence Address: MICHAEL P. MORRIS Dec. 20, 1996 (DE) ............................... 19653969.2 BOEHRINGERINGELHEMI USA CORPORA Dec. 16, 1997 (EP) ......................... PCT/EP97/07062 TION Publication Classification 900 RIDGEBURY RD, P. O. BOX 368 RIDGEFIELD, CT 06877-0368 (US) (51) Int. Cl. A63L/46 (2006.01) (73) Assignee: Boehringer Ingelheim Pharma A63L/437 (2006.01) KG, Ingelheim (DE) (52) U.S. Cl. ......................................... 514/291; 514/299 (57) ABSTRACT (21) Appl. No.: 12/338,812 The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propel (22) Filed: Dec. 18, 2008 lant-free aerosols. US 2009/0099225A1 Apr. 16, 2009 METHOD FOR THE PRODUCTION OF 0008 All substances which are suitable for application by PROPELLANT GAS-FREE AEROSOLS FROM inhalation and which are soluble in the specified solvent can AQUEOUSMEDICAMENT PREPARATIONS be used as pharmaceuticals in the new preparations. Pharma ceuticals for the treatment of diseases of the respiratory pas RELATED APPLICATIONS sages are of especial interest.
  • Different Strategies for Using Topical Corticosteroids in People with Eczema (Protocol)

    Different Strategies for Using Topical Corticosteroids in People with Eczema (Protocol)

    Cochrane Database of Systematic Reviews Different strategies for using topical corticosteroids in people with eczema (Protocol) Chalmers JR, Axon E, Harvey J, Santer M, Ridd MJ, Lawton S, Langan S, Roberts A, Ahmed A, Muller I, Long CM, Panda S, Chernyshov P, Carter B, Williams HC, Thomas KS Chalmers JR, Axon E, Harvey J, Santer M, Ridd MJ, Lawton S, Langan S, Roberts A, Ahmed A, Muller I, Long CM, Panda S, Chernyshov P, Carter B, Williams HC, Thomas KS. Different strategies for using topical corticosteroids in people with eczema. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No.: CD013356. DOI: 10.1002/14651858.CD013356. www.cochranelibrary.com Different strategies for using topical corticosteroids in people with eczema (Protocol) Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 4 METHODS ...................................... 4 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 12 CONTRIBUTIONSOFAUTHORS . 13 DECLARATIONSOFINTEREST . 14 SOURCESOFSUPPORT . 15 Different strategies for using topical corticosteroids in people with eczema (Protocol) i Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Different strategies for using topical corticosteroids in